Urtoxazumab

Urtoxazumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	E. coli Shiga-like toxin II B subunit
Identifiers
CAS Number	502496-16-4
ATC code	none
Chemical data
Formula	C6414H9934N1718O2010S40
Molar mass	144.6 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Urtoxazumab is a humanized monoclonal antibody against diarrhoea caused by Escherichia coli, serotype O121. The drug is designed to bind to a toxin of this bacterium, so that it can be more easily broken down and eliminated from the body.^[1]^[2]

References

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ López, EL; Contrini, MM; Glatstein, E; González Ayala, S; Santoro, R; Allende, D; Ezcurra, G; Teplitz, E; Koyama, T; Matsumoto, Y (2009). "Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients". Antimicrobial agents and chemotherapy. doi:10.1128/AAC.00343-09. PMID 19822704.

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.